Amplia Therapeutics Amplia Therapeutics is a pharmaceutical company developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. | ![]() Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. | ![]() RS Research RS Research is a pharmaceutical company developing nanomedicines based on innovative drug delivery platforms for targeted cancer therapy. | ||
Founding Date | Founding Date 2016 | Founding Date 1991 | Founding Date 2017 | Founding Date 2015 |
Type | Type Public | Type Subsidiary | Type Public | Type Private |
Tags | ||||
Locations | Locations Melbourne, AU HQ | Locations Sunnyvale, US HQ | Locations Cambridge, US HQ Toronto, CA New York, US Stony Brook, US | Locations Epalinges, CH HQ |
Employees | Employees N/A | Employees 6551% decrease | Employees 2456% decrease | Employees 254% decrease |
Valuation ($) | Valuation ($) 28.5 m | Valuation ($) N/A | Valuation ($) 165 m | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $729.7m (FY, 2014) | Revenue (est.) $70m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $40.4m (FY, 2014) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $4.8m (FY, 2026) | Gross profit $689.3m (FY, 2014) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($7.7m) (FY, 2026) | Net income $86.1m (FY, 2014) | Net income $22.4m (FY, 2025) | Net income N/A |

Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View company
Black Diamond Therapeutics is a biotechnology company.
View company
RS Research is a pharmaceutical company developing nanomedicines based on innovative drug delivery platforms for targeted cancer therapy.
View company